Look K - Search Results

1

Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.

Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC; Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee; Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Trimble EL, et al. Among authors: look k. Int J Gynecol Cancer. 2010 Oct;20(7):1290-8. doi: 10.1111/IGC.0b013e3181ee1c01. Int J Gynecol Cancer. 2010. PMID: 21151709 Free PMC article. Review.

2

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study.

Armstrong DK, Blessing JA, Look KY, Schilder R, Nunez ER. Armstrong DK, et al. Among authors: look ky. Invest New Drugs. 2003 Aug;21(3):373-7. doi: 10.1023/a:1025490818450. Invest New Drugs. 2003. PMID: 14578687 Clinical Trial.

3

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Tewari KS, et al. Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27. Lancet. 2017. PMID: 28756902 Free PMC article. Clinical Trial.

4

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. McGuire WP, et al. Among authors: look ky. N Engl J Med. 1996 Jan 4;334(1):1-6. doi: 10.1056/NEJM199601043340101. N Engl J Med. 1996. PMID: 7494563 Free article. Clinical Trial.

5

Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. McGuire WP, et al. Among authors: look ky. Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7. Semin Oncol. 1996. PMID: 8941409 Clinical Trial.

6

Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. McGuire WP, et al. Among authors: look ky. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-13-S2-16. Semin Oncol. 1997. PMID: 9045329 Clinical Trial.

7

Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiation.

Look K. Look K. Int J Gynecol Cancer. 2002 May-Jun;12(3):237-49. doi: 10.1046/j.1525-1438.2002.01119.x. Int J Gynecol Cancer. 2002. PMID: 12060444 Review.

8

Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Look KY, Blessing JA, Michener CM, Rubin S, Ramirez PT; Gynecologic Oncology Group Study. Look KY, et al. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):773-8. doi: 10.1111/j.1525-1438.2007.01080.x. Int J Gynecol Cancer. 2008. PMID: 17892452 Clinical Trial.

9

The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.

Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. Barlow TS, et al. Among authors: look ky. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):496-500. doi: 10.1111/j.1525-1438.2006.00573.x. Int J Gynecol Cancer. 2006. PMID: 16681717

10

Coexistence of metastatic neuroendocrine carcinoma of the uterine cervix with human immunodeficiency virus infection.

Balega J, Ulbright TM, Look KY. Balega J, et al. Among authors: look ky. Int J Gynecol Cancer. 2001 Jul-Aug;11(4):334-7. doi: 10.1046/j.1525-1438.2001.011004334.x. Int J Gynecol Cancer. 2001. PMID: 11520378

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters